Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Jan 23;135(4):352–362. doi: 10.1161/CIRCULATIONAHA.116.025253

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2016 The Authors.

Circulation is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial-NoDervis License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.

PMC Copyright notice

Figure 2. — Effect of alirocumab on VLDL-TG fractional clearance rates (A) and production rates (B). FCR of VLDL-TG (mean±SE) was determined by stable isotopic enrichment of glycerol in each sample of isolated VLDL over 48 hours. VLDL-TG PR (mean±SE) was calculated using the FCR and the plasma pool size of TG in VLDL. Alirocumab treatment did not affect either the FCR or the PR of VLDL-TG compared with placebo. FCR indicates fractional clearance rate; PR, production rate; TG, triglycerides; and VLDL, very low-density lipoprotein.